1,420 reports of this reaction
8.0% of all DRONEDARONE reports
#1 most reported adverse reaction
ATRIAL FIBRILLATION is the #1 most commonly reported adverse reaction for DRONEDARONE, manufactured by Sanofi-Aventis U.S. LLC. There are 1,420 FDA adverse event reports linking DRONEDARONE to ATRIAL FIBRILLATION. This represents approximately 8.0% of all 17,724 adverse event reports for this drug.
Patients taking DRONEDARONE who experience atrial fibrillation should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ATRIAL FIBRILLATION is moderately reported among DRONEDARONE users, representing a notable but not dominant share of adverse events.
In addition to atrial fibrillation, the following adverse reactions have been reported for DRONEDARONE:
The following drugs have also been linked to atrial fibrillation in FDA adverse event reports:
ATRIAL FIBRILLATION has been reported as an adverse event in 1,420 FDA reports for DRONEDARONE. This does not prove causation, but indicates an association observed in post-market surveillance data.
ATRIAL FIBRILLATION accounts for approximately 8.0% of all adverse event reports for DRONEDARONE, making it one of the most commonly reported side effect.
If you experience atrial fibrillation while taking DRONEDARONE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.